External validation of the N descriptor in the proposed tumour-node-metastasis subclassification for lung cancer: the crucial role of histological type, number of resected nodes and adjuvant therapy.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
01 12 2020
Historique:
received: 21 01 2020
revised: 27 04 2020
accepted: 01 05 2020
pubmed: 10 8 2020
medline: 22 6 2021
entrez: 10 8 2020
Statut: ppublish

Résumé

Overlapping survival curves for N1b (multiple N1 stations), N2a2 (single N2 station + N1 involvement) and N2a1 (skip N2 metastasis) limit the current tumour-node-metastasis (TNM) node (N) subclassification for node involvement. We validated externally the proposed subclassification. Clinical records from a multicentric database comprising 1036 patients with pulmonary adenocarcinoma (ADC) or squamous cell carcinoma with N1/N2 involvement who underwent, from January 2002 to December 2014, complete lung resections were retrospectively reviewed. Patients were categorized according to the 8th TNM N subclassification proposal. Histological type, number of resected nodes (#RN) and adjuvant therapy (ADJ) were considered limiting factors. No difference in the 5-year overall survival (-OS) was noted between N1b and N2a1 (49.6% vs 44.8%, P = 0.72); instead, the 5-year-OS was significantly improved in patients with squamous cell carcinoma (63% in N1b vs 30.7% in N2a1, P = 0.04). In patients with ADC, the 5-year-OS was better in those with N2a1 than with N1b (50.6% vs 37.5%, P = 0.09). When we compared N1b with N2a2, the 5-year-OS was statistically significant (49.6% vs 32.8%, P = 0.02); considering only patients with squamous cell carcinoma (63% vs 25.8%, P = 0.003), #RN >10 (63.2% vs 35.3%, P = 0.05) and without ADJ (56.4% vs 24.5%, P = 0.02), the 5-year-OS was significantly different. Differences were not significant for ADC, #RN <10 and ADJ. Finally, the 5-year-OS was statistically significant when we compared N2a1 with N2a2 of the total cohort (44.8% vs 32.8%, P = 0.04), in ADC (5-year-OS 50.6% vs 36.5%, P = 0.04) and #RN >10 (5-year-OS 49.8% vs 32.1%, P = 0.03) without ADJ. Histological type, ADJ and #RN are relevant prognostic factors in N + non-small-cell lung cancer. Considering these results, we may better interpret the prognosis prediction limits of the proposed 8th TNM subclassification for the N descriptor.

Identifiants

pubmed: 32770184
pii: 5885289
doi: 10.1093/ejcts/ezaa215
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1236-1244

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Marco Chiappetta (M)

Università Cattolica del Sacro Cuore, Rome, Italy.
Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Filippo Lococo (F)

Università Cattolica del Sacro Cuore, Rome, Italy.
Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Giovanni Leuzzi (G)

Thoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Isabella Sperduti (I)

Biostatistics, Regina Elena National Cancer Institute, Rome, Italy.

Leonardo Petracca-Ciavarella (L)

Università Cattolica del Sacro Cuore, Rome, Italy.
Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Emilio Bria (E)

Università Cattolica del Sacro Cuore, Rome, Italy.
Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Felice Mucilli (F)

Department of General and Thoracic Surgery, University Hospital "SS. Annunziata", Chieti, Italy.

Pier Luigi Filosso (PL)

Department of Thoracic Surgery, University of Turin, San Giovanni Battista Hospital, Turin, Italy.

Giovanni Battista Ratto (GB)

Division of Thoracic Surgery, IRCCS AOU "San Martino" IST, Genoa, Italy.

Lorenzo Spaggiari (L)

Thoracic Surgery Division, European Institute of Oncology, University of Milan, Milan, Italy.

Francesco Facciolo (F)

Thoracic Surgery, Regina Elena National Cancer Institute, Rome, Italy.

Stefano Margaritora (S)

Università Cattolica del Sacro Cuore, Rome, Italy.
Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH